STAAR Surgical Stock Forecast, Price & News

+0.61 (+0.42 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume372,470 shs
Average Volume664,866 shs
Market Capitalization$6.92 billion
P/E Ratio670.53
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAAR Surgical logo

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.37 out of 5 stars

Medical Sector

770th out of 2,100 stocks

Ophthalmic Goods Industry

4th out of 8 stocks

Analyst Opinion: 1.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

Is STAAR Surgical a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" STAAR Surgical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STAA, but not buy additional shares or sell existing shares.
View analyst ratings for STAAR Surgical
or view top-rated stocks.

What stocks does MarketBeat like better than STAAR Surgical?

Wall Street analysts have given STAAR Surgical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but STAAR Surgical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for STAAR Surgical

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) posted its quarterly earnings results on Wednesday, May, 5th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.22. The medical instruments supplier earned $50.75 million during the quarter, compared to analysts' expectations of $43.50 million. STAAR Surgical had a trailing twelve-month return on equity of 10.93% and a net margin of 6.17%.
View STAAR Surgical's earnings history

How has STAAR Surgical's stock been impacted by Coronavirus (COVID-19)?

STAAR Surgical's stock was trading at $28.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STAA shares have increased by 426.6% and is now trading at $147.51.
View which stocks have been most impacted by COVID-19

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $215 million-$217 million, compared to the consensus revenue estimate of $204.02 million.

What price target have analysts set for STAA?

5 Wall Street analysts have issued 12-month target prices for STAAR Surgical's shares. Their forecasts range from $58.00 to $150.00. On average, they anticipate STAAR Surgical's share price to reach $84.25 in the next year. This suggests that the stock has a possible downside of 42.9%.
View analysts' price targets for STAAR Surgical
or view top-rated stocks among Wall Street analysts.

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the following people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 67, Pay $1.06M) (LinkedIn Profile)
  • Mr. Patrick F. Williams, Chief Financial Officer (Age 48, Pay $449.77k)
  • Dr. Keith Holliday, Chief Technology Officer (Age 58, Pay $544.82k) (LinkedIn Profile)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations and Director of Markets - Europe & China (Age 56, Pay $551.59k)
  • Dr. Scott D. Barnes M.D., Chief Medical Officer (Age 58, Pay $627.25k)
  • Mr. Graydon C. Hansen, Chief Manufacturing Officer & Sr. VP of Global Operations (Age 62) (LinkedIn Profile)
  • Mr. Brian Moore, VP of Investor, Media Relations & Corp. Devel.
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 59) (LinkedIn Profile)
  • Mr. William Goodmen, VP of Global HR (Age 66) (LinkedIn Profile)
  • Mr. James Francese, Sr. VP of Commercial Operations - North America & APAC (Age 57)

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical CEO Caren Mason on Caren Mason has an approval rating of 68% among STAAR Surgical's employees.

Who are some of STAAR Surgical's key competitors?

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), The Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), The Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.82%), Baillie Gifford & Co. (8.89%), Palo Alto Investors LP (3.87%), Geneva Capital Management LLC (2.01%), Geode Capital Management LLC (1.69%) and Ensign Peak Advisors Inc (1.56%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Samuel J Gesten and Scott D Barnes.
View institutional ownership trends for STAAR Surgical

Which major investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Geneva Capital Management LLC, Morgan Stanley, TimesSquare Capital Management LLC, Royal Bank of Canada, Defender Capital LLC., Loomis Sayles & Co. L P, and Pura Vida Investments LLC. Company insiders that have sold STAAR Surgical company stock in the last year include Broadwood Partners, LP, Caren L Mason, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, and Samuel J Gesten.
View insider buying and selling activity for STAAR Surgical
or view top insider-selling stocks.

Which major investors are buying STAAR Surgical stock?

STAA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Baillie Gifford & Co., E Fund Management Co. Ltd., Bank of New York Mellon Corp, Principal Financial Group Inc., Principal Financial Group Inc., Goldman Sachs Group Inc., and Northern Trust Corp.
View insider buying and selling activity for STAAR Surgical
or or view top insider-buying stocks.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $147.51.

How much money does STAAR Surgical make?

STAAR Surgical has a market capitalization of $6.92 billion and generates $163.46 million in revenue each year. The medical instruments supplier earns $5.91 million in net income (profit) each year or $0.35 on an earnings per share basis.

How many employees does STAAR Surgical have?

STAAR Surgical employs 575 workers across the globe.

Does STAAR Surgical have any subsidiaries?

The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.

When was STAAR Surgical founded?

STAAR Surgical was founded in 1982.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is

Where are STAAR Surgical's headquarters?

STAAR Surgical is headquartered at 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.